This article is sponsored by ODAIA and was written, edited, and published in alignment with our Emerj sponsored content guidelines. Learn more about our thought leadership and content creation services on our Emerj Media Services page.
Pharma is leaving revenue and patients on the table because strategy isn’t reaching the field with the speed or clarity required to drive real-world action. Insights move too slowly and inconsistently to guide daily decisions, creating an execution gap that results in misaligned activity, wasted spend, and missed treatment opportunities.
The scale of commercial risk is substantial. According to research published in PubMed Central, the U.S. pharmaceutical industry spent an estimated $20.4 billion on detailing and direct marketing to physicians in a single benchmark year. While that structural investment is designed to shape prescribing behavior, its effectiveness depends entirely on whether the right insight reaches the right representative before the decision moment has passed.
The evidence suggests it frequently does not. A peer-reviewed analysis of 102 drug launches published in PubMed Central examined the systematic weakness in commercial forecasting and found that 55.9% of products had forecast errors exceeding ±50%, with projections often significantly overstating expected performance. The gap between what commercial teams project and what actually happens in the market is not an exception — it is the norm.
